Anika Therapeutics, Inc. Disposal Group, Including Discontinued Operation, Revenue
Anika Therapeutics, Inc. (ANIK) reported Disposal Group, Including Discontinued Operation, Revenue of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Income Statement › Other Income
us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue · last filed 2026-07-29
- Anika Therapeutics, Inc. disposal group, including discontinued operation, revenue for the quarter ending 2026-06-30 was $0.00.
- Anika Therapeutics, Inc. disposal group, including discontinued operation, revenue for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Anika Therapeutics, Inc. disposal group, including discontinued operation, revenue for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Anika Therapeutics, Inc. disposal group, including discontinued operation, revenue for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Anika Therapeutics, Inc. disposal group, including discontinued operation, revenue for fiscal 2025 was $2.71M, a 93.14% decline from fiscal 2024.
- Anika Therapeutics, Inc. disposal group, including discontinued operation, revenue for fiscal 2024 was $39.49M, a 13.90% decline from fiscal 2023.
- Anika Therapeutics, Inc. disposal group, including discontinued operation, revenue for fiscal 2023 was $45.87M.
| Period end | Disposal Group, Including Discontinued Operation, Revenue 3 month | Disposal Group, Including Discontinued Operation, Revenue 6 month | Disposal Group, Including Discontinued Operation, Revenue 9 month | Disposal Group, Including Discontinued Operation, Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-07-29 | $0.00 10-Q · filed 2026-07-29 | ||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $0.00 derived: sum of 2 quarters · filed 2026-03-03 | $0.00 derived: sum of 3 quarters · filed 2026-07-29 | $2.71M 10-K · filed 2026-03-03 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2026-07-29 | $2.71M 10-Q · filed 2025-11-05 | $10.31M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $0.00 10-Q · filed 2026-07-29 | $2.71M 10-Q · filed 2026-07-29 | $10.31M derived: sum of 3 quarters · filed 2026-07-29 | $19.51M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $2.71M 10-Q · filed 2025-05-09 | $10.31M derived: sum of 2 quarters · filed 2026-03-03 | $19.51M derived: sum of 3 quarters · filed 2026-03-03 | $30.70M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-12-31 | $7.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $16.80M derived: sum of 2 quarters · filed 2026-03-03 | $27.99M derived: sum of 3 quarters · filed 2026-03-03 | $39.49M 10-K · filed 2026-03-03 |
| 2024-09-30 | $9.19M 10-Q · filed 2025-11-05 | $20.39M derived: sum of 2 quarters · filed 2025-11-05 | $31.89M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $11.20M 10-Q · filed 2025-07-30 | $22.70M 10-Q · filed 2025-07-30 | ||
| 2024-03-31 | $11.50M 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | $45.87M 10-K · filed 2026-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |